Biofrontera (BFRI) Stock Price, News & Analysis

Company Overview

Biofrontera Inc. (NASDAQ:BFRI) is a commercial-stage biopharmaceutical company focused on dermatology. The company develops and markets prescription therapies for the treatment of skin conditions, with an emphasis on products that address actinic keratosis and other dermatologic diseases.

Its principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, which is used in combination with the BF-RhodoLED lamp in photodynamic therapy for actinic keratoses. Biofrontera also provides the BF-RhodoLED photodynamic therapy lamp system used by healthcare professionals to activate the treatment.

Biofrontera Inc. is based in the United States and operates as part of the broader Biofrontera corporate group, which has German roots and an international dermatology business. The company’s commercial activities are primarily focused on the U.S. market, where it supports the distribution, sales, and clinical use of its dermatology products.

Key Stats

• Today's Range: $1.27 to $1.33
• 50-Day Range: $1.05 to $1.61
• 52-Week Range: $0.55 to $1.66
• Volume: 375,462 shs
• Average Volume: 796,121 shs
• Market Capitalization: $19.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Biofrontera Stock Analysis - MarketRank™

Biofrontera scored higher than 25% of companies evaluated by MarketBeat, and ranked 790th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Biofrontera has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Biofrontera has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biofrontera are expected to grow in the coming year, from ($0.60) to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biofrontera is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biofrontera is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biofrontera has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.87% of the float of Biofrontera has been sold short.

Short Interest Ratio / Days to Cover

Biofrontera has a short interest ratio ("days to cover") of 0.38, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biofrontera has recently increased by 675.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biofrontera does not currently pay a dividend.

Dividend Growth

Biofrontera does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.66

News Sentiment

Biofrontera has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Biofrontera this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for BFRI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biofrontera insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.10% of the stock of Biofrontera is held by insiders.

Percentage Held by Institutions

10.08% of the stock of Biofrontera is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:BFRI
• CIK: 1858685
• Web: www.biofrontera-us.com
• Phone: 781-245-1325
• Fax: N/A
• Employees: 94
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.54 million
• Net Margins: -13.78%
• Pretax Margin: -13.72%
• Return on Equity: -145.81%
• Return on Assets: -31.30%

Debt

• Debt-to-Equity Ratio: 0.78
• Current Ratio: 1.18
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $41.71 million
• Price / Sales: 0.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.90 per share
• Price / Book: 1.47

Miscellaneous

• Outstanding Shares: 14,850,000
• Free Float: 13,649,000
• Market Cap: $19.60 million
• Optionable: No Data
• Beta: 0.83